title: Electrohydrodynamic encapsulation of cisplatin in poly (lactic-co-glycolic acid) nanoparticles for controlled drug delivery.
abstract: Targeted delivery of potent, toxic chemotherapy drugs, such as cisplatin, is a significant area of research in cancer treatment. In this study, cisplatin was successfully encapsulated with high efficiency (>70%) in poly (lactic-co-glycolic acid) polymeric nanoparticles by using electrohydrodynamic atomization (EHDA) where applied voltage and solution flow rate as well as the concentration of cisplatin and polymer were varied to control the size of the particles. Thus, nanoparticles were produced with three different drug:polymer ratios (2.5, 5 and 10wt% cisplatin). It was shown that smaller nanoparticles were produced with 10wt% cisplatin. Furthermore, these demonstrated the best sustained release (smallest burst release). By fitting the experimental data with various kinetic models it was concluded that the release is dependent upon the particle morphology and the drug concentration. Thus, these particles have significant potential for cisplatin delivery with controlled dosage and release period that are crucial chemotherapy parameters.
authors.affiliation: Mechanical Engineering, University College London, London, United Kingdom.
authors.forename: Maryam
authors.initials: M
authors.lastname: Parhizkar
authors.affiliation: Division of Biomaterials and Tissue Engineering, UCL Eastman Dental Institute, University College London, London, United Kingdom.
authors.forename: Philip J T
authors.initials: PJ
authors.lastname: Reardon
authors.affiliation: Division of Biomaterials and Tissue Engineering, UCL Eastman Dental Institute, University College London, London, United Kingdom.
authors.forename: Jonathan C
authors.initials: JC
authors.lastname: Knowles
authors.affiliation: Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford, United Kingdom.
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Browning
authors.affiliation: Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford, United Kingdom.
authors.forename: Eleanor
authors.initials: E
authors.lastname: Stride
authors.affiliation: UCL Cancer Institute, Department of Oncology, University College London, London, United Kingdom.
authors.forename: Pedley R
authors.initials: PR
authors.lastname: Barbara
authors.affiliation: Department of Physics & Astronomy, University College London, London, United Kingdom.
authors.forename: Anthony H
authors.initials: AH
authors.lastname: Harker
authors.affiliation: Mechanical Engineering, University College London, London, United Kingdom. Electronic address: m.edirisinghe@ucl.ac.uk.
authors.forename: Mohan
authors.initials: M
authors.lastname: Edirisinghe
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002945:Cisplatin / Q000008:administration & dosage*; D016503:Drug Delivery Systems; D006018:Glycols; D006801:Humans; D019344:Lactic Acid; D053758:Nanoparticles; D010316:Particle Size; D011100:Polyglycolic Acid
chemical_list: D000970:Antineoplastic Agents; D006018:Glycols; D011100:Polyglycolic Acid; D019344:Lactic Acid; D002945:Cisplatin
keywords: Cancer chemotherapy; Cisplatin delivery; Controlled release; Electrohydrodynamic atomization; Nanoparticle